Taken together, KCTD10 suppresses lung cancer progression and immune escape via the β-catenin/PD-L1 axis, and its expression is tightly regulated by METTL14-dependent m6A modification, highlighting its potential as a therapeutic target. This evidence concerns the gene METTL14 and lung carcinoma.